CD47 and acute myeloid leukemia: In contradistinction, the introduction of TIGIT inhibitors could reprogram TIGIT+ M2 macrophages to the M1 phenotype, leading to increased CD47-mediated phagocytosis and ultimately benefiting the prognosis of patients with acute myeloid leukemia (AML) [57].